Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Population Council and Duchesnay Announce New International License Agreement for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Duchesnay Announces the Launch of Vablys (dequalinium chloride vaginal tablets), an Antiseptic and Anti-Infective Treatment for Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for the Chronic Management of Urea Cycle Disorders (UCDs)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Duchesnay

    Menu

    Duchesnay

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Duchesnay

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Brand Institute Partners on Brand Name Development for FDA Approved Treatment for the Chronic Management of Urea Cycle Disorders (UCDs)

              Details:

              PHEBURANE® (sodium phenylbutyrate) is indicated adjunctive therapy to standard of care, which includes dietary management, for chronic management of adult and pediatric patients with UCDs.

              Lead Product(s): Sodium Phenylbutyrate

              Therapeutic Area: Genetic Disease Product Name: Pheburane

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Brand Institute

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Duchesnay

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Duchesnay Announces the Launch of Vablys (dequalinium chloride vaginal tablets), an Antiseptic and Anti-Infective Treatment for Bacterial Vaginosis

              Details:

              Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.

              Lead Product(s): Dequalinium Chloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Vablys

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Duchesnay

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®

              Details:

              As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.

              Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Population Council

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Duchesnay

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine

              Details:

              The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of their own home.

              Lead Product(s): Ospemifene

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Plushcare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY